Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
175.6 USD | -4.73% | +3.11% | -19.08% |
May. 07 | Wolfe Upgrades Insulet to Outperform From Peerperform With $200 Price Target | MT |
May. 07 | Wolfe Research Upgrades Insulet to Outperform From Peer Perform, Price Target is $200 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 61% by 2026.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 61.99 and 48.36 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.08% | 12.29B | B- | ||
-4.66% | 183B | C+ | ||
-1.01% | 108B | C | ||
-4.20% | 67.51B | A | ||
+2.68% | 50.67B | B- | ||
+9.12% | 44.7B | B- | ||
+3.01% | 40.95B | B+ | ||
+4.13% | 26.71B | A- | ||
+3.31% | 26.8B | B | ||
+12.96% | 24.62B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PODD Stock
- Ratings Insulet Corporation